The in vitro activity of E4868 was compared with that of ciprofloxacin and temafloxacin in a multicenter study. More than 90% of Enterobacteriaceae and 82% of the 651 isolates of Pseudomonas aeruginosa, as well as > 95% of the oxacillin-susceptible staphylococci, 100% of the beta-hemolytic streptococci, and 76% of the enterococcal isolates were susceptible to E4868 (minimum inhibitory concentrations, < or = 2 micrograms/ml). E4868 was generally equivalent or slightly less active than ciprofloxacin against the Enterobacteriaceae and Pseudomonas and more active against staphylococci and beta-hemolytic streptococci. The activity of E4868 was generally equivalent to or slightly greater than that of temafloxacin against all major groups of organisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0732-8893(93)90040-e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and tolerability of fluoroquinolones.
Clin Cornerstone
May 2004
University of Illinois at Chicago, Illinois 60612, USA.
Clinical trials in patients with community- and hospital-acquired infections have established that the clinical effectiveness and safety of fluoroquinolones are similar to beta-lactam and macrolide agents. The most common drug-related adverse effects (AEs) with fluoroquinolone therapy involve the gastrointestinal tract and central nervous system and are usually transient and mild to moderate in severity. However, serious toxic reactions have led to the limited and restrictive use of trovafloxacin in the United States and the withdrawal of temafloxacin and grepafloxacin from worldwide markets.
View Article and Find Full Text PDFLevofloxacin-induced autoimmune hemolytic anemia.
Ann Pharmacother
September 2003
Department of Clinical Pharmacy Services, David Grant USAF Medical Center, Travis Air Force Base, CA, USA.
Objective: To report a case of autoimmune hemolytic anemia (AIHA) secondary to levofloxacin.
Case Summary: An 82-year-old white man was treated with levofloxacin 500 mg/d for cellulitis. Three days following completion of levofloxacin therapy, the patient presented to the emergency department with severe jaundice, dizziness, and loss of vision.
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Jpn J Antibiot
June 2002
Research Laboratories, Toyama Chemical Co. Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan.
Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration. Following results were obtained. 1.
View Article and Find Full Text PDFOral contraceptive efficacy and antibiotic interaction: a myth debunked.
J Am Acad Dermatol
June 2002
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, USA.
The purpose of this study was to review the pharmacokinetic and clinical literature regarding the efficacy of oral contraceptives when used concomitantly with antibiotic therapy. Relevant literature was identified by searching MEDLINE and EMBASE. Other sources were located by consulting the bibliographies of the material collected from MEDLINE and EMBASE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!